Cleveland Clinic clinicians alert other physicians to adverse events related to immune checkpoint inhibitors.
Surgical de-escalation is part of a larger movement of de-escalation of multidisciplinary breast cancer treatment. The challenge is to balance the outcomes.
A new study examines the use of a seven-gene predictive DCIS biosignature to assess when endocrine therapy may benefit patients following breast-conserving surgery.
Most patients who have breast cancer risk-reduction surgery choose NSM and are pleased with the results. But evidence is limited on whether NSM is effective in preventing breast cancer, especially over the long term.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Women with wound complications after mastectomy and immediate breast reconstruction do not have a higher risk of breast cancer recurrence, despite potential delays in adjuvant therapy, says new study.